Belser v. Quest Diagnostics Inc

District Court, D. South Carolina·Decided March 11, 2021·No. 3:16-cv-00972·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF SOUTH CAROLINA COLUMBIA DIVISION H. Freeman Belser, Esquire, as Personal ) Representative of the □□□□□□□□□□□□□□□□□□□□□□□□□□ No. 3:16-0972-MBS ME; and Amy Williams, individually, ) ) Plaintiffs, ) ) vs. ) ORDER AND OPINION ) Quest Diagnostics, Inc.; Athena ) Diagnostics, Inc.; and ADI Holdings, ) Inc., ) ) Defendants. ) oo) Plaintiffs Amy Elizabeth Williams, as the Personal Representative of the Estatc ==! ME““Decedent’”),' and Amy Elizabeth Williams, individually (together, “Plaintiff’), filed this action in the Court of Common Pleas for Richland County, South Carolina, on February 24, 2016 against Defendants Quest Diagnostics, Inc. (“Quest”); Athena Diagnostics, Inc. (“Athena”); and ADI Holdings, Inc. (together, “Defendants”).” Defendants removed the complaint on March 28, 2016 on the grounds of diversity jurisdiction. This matter currently is before the court on Defendants’ motions for attorney’s fees, both of which are grounded on allegations of discovery abuse. Defendants’ motion filed on October 15, 2020 arises out of Defendants’ motion for sanctions against Plaintiff individually and her counsel,

'The current personal representative, H. Freeman Belser, Esquire, was substituted by order filed October 1, 2020. * Quest Diagnostics is the parent company of ADI Holding Company, Inc., and owns 100% of the shares of ADI Holding Company. ECF No. 3. ADI Holding Company, Inc., is the parent corporation of Athena Diagnostics, Inc. and owns 100% of the shares of Athena Diagnostics, Inc. ECF No. 4.

which motion was granted during a two-hour omnibus hearing on September 29, 2020.3 Plaintiff filed a response in opposition to Defendants’ motion for attorney’s fees on March 3, 2021, after inadvertently failing to file the response with the court but timely disseminating it to Defendants. Defendants filed a reply on November 5, 2020.

The second motion for attorney’s fees arises from a motion for an order to show cause that was lodged against a material witness, Laurel Coons (“Coons”). Coons is or was a friend of Plaintiff4 who provided advice to Plaintiff and Plaintiff’s counsel. The motion for an order to show cause was granted at the September 29, 2020 omnibus hearing, and the order to show cause issued on October 13, 2020. There being no response to the order to show cause, Defendants moved for attorney’s fees on November 24, 2020. Counsel for Coons filed a response in opposition on December 18, 2020; however, the response was withdrawn and counsel relieved on January 12, 2021

at the request of Coons. Coons, proceeding pro se, filed a response in opposition to Defendants’ motion on February 11, 2021. Defendants filed a reply on February 18, 2021. BACKGROUND This case has a lengthy factual and procedural history. Briefly, Decedent began suffering febrile focal motor seizures beginning around four months of age. Decedent was treated by a pediatric neurologist who prescribed carbamazepine and lamotrigine. The administration of these medications was not effective.

3The court heard four discovery motions at the September 29, 2020 hearing. 4Plaintiff has known Coons since they were in high school. ECF No. 101-17, 3. Plaintiff went to a different college but then reconnected with Coons in 2008 after Decedent’s passing. Id. at 4. They had a falling out in 2009 and then reconnected in 2010. Plaintiff commenced dating her current husband and stopped talking to Coons for a while. Id. at 6. They reconnected again in August 2014. Id. at 6. Their relationship now generally relates to the within litigation. Id. at 7. 2 Decedent’s DNA was provided to Athena in May 2007 for an SCN1A DNA Sequencing Clinical Diagnostic Test. ECF No. 165-11. An SCN1A DNA Sequencing Clinical Report (the “2007 Report”) was issued by Athena on June 30, 2007. ECF No. 165-12. The 2007 Report noted that Decedent possessed a DNA mutation in the SCN1A gene classified as a “#4: variant of unknown

significance” (“VUS”).5 Decedent was treated with increasing doses of carbamazepine. Tragically, Decedent died on January 5, 2008 following a traumatic seizure. On or about September 29, 2014, Plaintiff learned that the “variant of unknown significance” identified on the 2007 Report had since been reported as pathogenic. Decedent’s variant was reanalyzed by Athena and a revised report was issued on January 30, 2015 (the “2015 Report.”). The 2015 Report indicated that “[a]nalysis of this individual’s SCN1A gene identified a DNA sequence variant that has been reported in the literature to be associated with SMEI [Severe Myoclonic

Epilepsy of Infancy] or SMEB [borderline SMEI], the severe phenotypes associated with SCN1A mutations.” ECF No. 165-27, 2. SMEI is also known as Dravet’s syndrome. Carbamazepine is contraindicated for Dravet’s syndrome. According to Plaintiff’s expert witness, Decedent’s neurologist would have managed Decedent differently had Athena classified Decedent’s mutation as a pathogenic variant in 2007. Plaintiff’s expert opined that, had Decedent not been prescribed carbamazepine, he would have been more resistant to seizures and therefore, more likely than not,

5According to the 2007 Report, “Since these types of sequence variants are similar to those observed in both disease-associated mutations at other nucleotide positions and in benign polymorphisms, the nature of this variation precluded clear interpretation. These DNA sequence variants may or may not alter the functional aspects of the SCN1A gene and/or its protein product. While methodologically accurate, the results of this analysis cannot be definitively interpreted due to the absence of published studies correlating these variant(s) with clinical presentation and/or pathology. Therefore, based on this single analysis, it is not possible to conclude with any reasonable degree of clinical certainty at this time whether or not this variant is associated with the phenotype in question.” ECF No. 165-12, 2. 3 he would not have experienced the severe seizure that caused his death. ECF No. 153-9, 9-10. Plaintiff filed an amended complaint on June 2, 2016, in which she asserted claims of negligence/gross negligence resulting in the wrongful death of Decedent, a survival action based on the suffering Decedent experienced before death, and causes of action for negligent

misrepresentation, constructive fraud, and violation of the South Carolina Unfair Trade Practices Act. By order filed October 18, 2018, the court determined that Plaintiff’s causes of action for wrongful death, survivorship, negligent misrepresentation, and constructive fraud sounded in both medical malpractice and ordinary negligence. To the extent Plaintiff’s claims sounded in medical malpractice, the court concluded that Plaintiff’s claims are barred by the applicable six-year statute of repose. See S.C. Code Ann. § 15-79-110(6). The question became, then, whether Plaintiff could show the failure to identify Decedent’s variant in 2007 as pathogenic was the result of simple

negligence, such as administrative error. By order filed November 5, 2020, the court concluded that no reasonable jury could find Defendants erred in classifying Decedent’s variant as a VUS, or that any misclassification was the result of nonmedical, administrative, ministerial, or routine care.6 The court entered judgment in favor of Defendants as to all causes of action. MOTIONS FOR ATTORNEY’S FEES Pursuant to Fed. R. Civ. P. 37(a)(5)(A), (A) If [a Motion to Compel] Is Granted (or Disclosure or Discovery Is Provided After Filing).

Free access — add to your briefcase to read the full text and ask questions with AI

Belser v. Quest Diagnostics Inc, (D.S.C. 2021).

Belser v. Quest Diagnostics Inc (Belser v. Quest Diagnostics Inc) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Hensley v. Eckerhart
461 U.S. 424 (Supreme Court, 1983)
Blanchard v. Bergeron
489 U.S. 87 (Supreme Court, 1989)
Grissom v. the Mills Corp.
549 F.3d 313 (Fourth Circuit, 2008)
Johnson v. Georgia Highway Express, Inc.
488 F.2d 714 (Fifth Circuit, 1974)